236 related articles for article (PubMed ID: 17211028)
1. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.
Choudhry NK; Avorn J; Antman EM; Schneeweiss S; Shrank WH
Health Aff (Millwood); 2007; 26(1):186-94. PubMed ID: 17211028
[TBL] [Abstract][Full Text] [Related]
2. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Moran A; Goldman L
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
[TBL] [Abstract][Full Text] [Related]
3. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
5. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
[TBL] [Abstract][Full Text] [Related]
6. Long-term adherence with cardiovascular drug regimens.
Kulkarni SP; Alexander KP; Lytle B; Heiss G; Peterson ED
Am Heart J; 2006 Jan; 151(1):185-91. PubMed ID: 16368315
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
[TBL] [Abstract][Full Text] [Related]
8. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis.
van der Elst ME; Bouvy ML; de Blaey CJ; de Boer A
Clin Ther; 2005 Nov; 27(11):1806-14. PubMed ID: 16368451
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.
Choudhry NK; Brennan T; Toscano M; Spettell C; Glynn RJ; Rubino M; Schneeweiss S; Brookhart AM; Fernandes J; Mathew S; Christiansen B; Antman EM; Avorn J; Shrank WH
Am Heart J; 2008 Jul; 156(1):31-6. PubMed ID: 18585494
[TBL] [Abstract][Full Text] [Related]
10. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
Cole JA; Norman H; Weatherby LB; Walker AM
Pharmacotherapy; 2006 Aug; 26(8):1157-64. PubMed ID: 16863491
[TBL] [Abstract][Full Text] [Related]
11. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.
Gislason GH; Rasmussen JN; Abildstrøm SZ; Gadsbøll N; Buch P; Friberg J; Rasmussen S; Køber L; Stender S; Madsen M; Torp-Pedersen C
Eur Heart J; 2006 May; 27(10):1153-8. PubMed ID: 16399775
[TBL] [Abstract][Full Text] [Related]
12. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients.
Pilote L; Beck C; Richard H; Eisenberg MJ
CMAJ; 2002 Aug; 167(3):246-52. PubMed ID: 12186169
[TBL] [Abstract][Full Text] [Related]
13. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
14. Full coverage for preventive medications after myocardial infarction.
Choudhry NK; Avorn J; Glynn RJ; Antman EM; Schneeweiss S; Toscano M; Reisman L; Fernandes J; Spettell C; Lee JL; Levin R; Brennan T; Shrank WH;
N Engl J Med; 2011 Dec; 365(22):2088-97. PubMed ID: 22080794
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization.
Tuppin P; Neumann A; Danchin N; de Peretti C; Weill A; Ricordeau P; Allemand H
Arch Cardiovasc Dis; 2010; 103(6-7):363-75. PubMed ID: 20800800
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
17. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
18. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Hudson M; Richard H; Pilote L
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
[TBL] [Abstract][Full Text] [Related]
19. An intervention to improve secondary prevention of coronary heart disease.
Bailey TC; Noirot LA; Blickensderfer A; Rachmiel E; Schaiff R; Kessels A; Braverman A; Goldberg A; Waterman B; Dunagan WC
Arch Intern Med; 2007 Mar; 167(6):586-90. PubMed ID: 17389290
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Wang M; Moran AE; Liu J; Coxson PG; Heidenreich PA; Gu D; He J; Goldman L; Zhao D
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):78-85. PubMed ID: 24425706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
